EDITORIAL
Idiopathic Pulmonary Fibrosis: The dawn of a new era
 
More details
Hide details
1
Editor-in-Chief Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece
CORRESPONDING AUTHOR
Demosthenes Bouros   

Dept. of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis 68100 Alexandroupolis, Greece
 
Pneumon 2014;27(2):117–119
 
 
REFERENCES (21)
1.
Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
 
2.
Travis WD, Costabel U, Hansell DM, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-748.
 
3.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
 
4.
Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005; 26:693-702.
 
5.
The IPF Clinical Research Network authors. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med 2012;366:1968-1977.
 
6.
The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014;370:2093-2101.
 
7.
Richeldi L, du Bois RM, Raghu G, et al, for the INPULSIS Trial Investigators. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014;370:2071-2082.
 
8.
Richeldi L, Costabel U, Selman M, et al. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. N Engl J Med 2011;365:1079-1087.
 
9.
Bouros D: Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011;377:1727-1729.
 
10.
King TE Jr., Bradford WZ, Castro-Bernardini S, et al, for the ASCEND Study Group. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 2014;370:2083-2092.
 
11.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
 
12.
Hunninghake GM. A New Hope for Idiopathic Pulmonary Fibrosis. N Engl J Med 2014;370:2142-2143.
 
13.
Kotsianidis I, Nakou E, Bouchliou I, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:1121-1130.
 
14.
Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, Bouros D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 2005;127:266-74.
 
15.
Tzouvelekis A, Bouros D. Anti-acid treatment for idiopathic pulmonary fibrosis. Lancet Respir Med 2013;1:348-349.
 
16.
Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med 2014;2:17-19.
 
17.
Tzouvelekis A, Bouros D. Steep barriers to overcome for successful application of stem cell treatment in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013;188:251-252.
 
18.
Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013;11:171.
 
19.
Tzouvelekis A, Antoniadis A, Bouros D. Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med 2011;17:368-373.
 
20.
Papiris SA, Triantafillidou C, Manali ED, et al. Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med 2013;7:19-31.
 
21.
Bouros D. Current therapy of idiopathic pulmonary fibrosis: primum non noccere! Pneumon 2012;25: 259-261.
 
eISSN:1791-4914
ISSN:1105-848X